American Century Companies Inc. Increases Stake in Stryker Co. (NYSE:SYK)

American Century Companies Inc. boosted its stake in Stryker Co. (NYSE:SYK) by 11.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 743,693 shares of the medical technology company’s stock after purchasing an additional 75,897 shares during the period. American Century Companies Inc.’s holdings in Stryker were worth $267,767,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Kohmann Bosshard Financial Services LLC purchased a new position in Stryker in the 4th quarter worth approximately $25,000. Dunhill Financial LLC increased its stake in shares of Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after buying an additional 37 shares during the period. Rakuten Securities Inc. increased its stake in shares of Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock valued at $28,000 after buying an additional 68 shares during the period. Centricity Wealth Management LLC purchased a new position in shares of Stryker during the fourth quarter valued at approximately $30,000. Finally, BankPlus Trust Department purchased a new position in shares of Stryker during the fourth quarter valued at approximately $33,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on SYK. Argus set a $450.00 target price on Stryker in a research note on Monday, February 3rd. Needham & Company LLC reissued a “buy” rating and set a $442.00 target price on shares of Stryker in a research note on Friday. Truist Financial boosted their target price on Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a research note on Thursday, January 30th. JMP Securities reissued a “market perform” rating on shares of Stryker in a research note on Tuesday, February 18th. Finally, Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and an average price target of $421.90.

Stryker Trading Down 0.8 %

Stryker stock opened at $371.38 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The stock has a market capitalization of $141.71 billion, a PE ratio of 47.86, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. The business’s fifty day moving average is $384.28 and its 200 day moving average is $373.93.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the firm earned $3.46 EPS. On average, sell-side analysts predict that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.90%. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.